Russell Skibsted is CFO at Processa Pharmaceuticals, Inc. (PCSA). They have made 10 open-market trades across 3 companies since 2011, most recently 2026-06-30.
CIK 0001308105
10 open-market purchases totalling $57K since 2011, never a sale. Across 8 scored buys the stock is down 19.4% at ninety days, and 24.5 points behind the S&P over the same stretch.
8 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| ALIM | 75,500 | $418K |
| BTX | 31,859 | $270K |
| PCSA | 16,689 | $28K |
| AOLS | 17,027 | — |
| Total | $716K |
Shares reported on the most recent Form 4, priced at the 2026-07-01 close. 1 holding could not be priced and is excluded from the total.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 25% | 25% | 0% |
| Avg Move | -3.2% | -8.0% | -19.4% |
| Alpha | -11.8% | -10.8% | -24.5% |
| Scored | 8 | 8 | 8 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| PCSA | BUY | 2026-06-30 | 2026-07-01 | $1.93 | $6K | +7.5% | +0.9% | -14.6% |
| PCSA | BUY | 2026-06-15 | 2026-06-16 | $2.22 | $6K | -7.5% | +5.7% | -10.4% |
| PCSA | BUY | 2026-05-29 | 2026-06-01 | $2.57 | $6K | -6.2% | -23.7% | -20.6% |
| PCSA | BUY | 2026-05-15 | 2026-05-19 | $2.97 | $6K | -2.7% | -18.4% | -18.0% |
| PCSA | BUY | 2026-04-30 | 2026-05-01 | $2.69 | $6K | -6.6% | -7.3% | -25.5% |
| PCSA | BUY | 2026-04-15 | 2026-04-17 | $2.97 | $6K | -17.2% | -16.9% | -32.3% |
| PCSA | BUY | 2026-03-31 | 2026-04-01 | $2.54 | $6K | +0.0% | -4.5% | -34.0% |
| BTX | BUY | 2017-08-23 | 2017-08-25 | $2.64 | $5K | +7.4% | -0.1% | -0.1% |
| AOLS | BUY | 2012-05-23 | 2012-05-23 | $0.24 | $2K | N/A | N/A | N/A |
| AOLS | BUY | 2011-05-18 | 2011-05-19 | $0.42 | $8K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.